128 related articles for article (PubMed ID: 9806738)
1. Interleukin-12 induces an effective antitumor response in malignant mesothelioma.
Caminschi I; Venetsanakos E; Leong CC; Garlepp MJ; Scott B; Robinson BW
Am J Respir Cell Mol Biol; 1998 Nov; 19(5):738-46. PubMed ID: 9806738
[TBL] [Abstract][Full Text] [Related]
2. Cytokine gene therapy of mesothelioma. Immune and antitumor effects of transfected interleukin-12.
Caminschi I; Venetsanakos E; Leong CC; Garlepp MJ; Robinson BW; Scott B
Am J Respir Cell Mol Biol; 1999 Sep; 21(3):347-56. PubMed ID: 10460752
[TBL] [Abstract][Full Text] [Related]
3. Differential antitumor effects of administration of recombinant IL-18 or recombinant IL-12 are mediated primarily by Fas-Fas ligand- and perforin-induced tumor apoptosis, respectively.
Hashimoto W; Osaki T; Okamura H; Robbins PD; Kurimoto M; Nagata S; Lotze MT; Tahara H
J Immunol; 1999 Jul; 163(2):583-9. PubMed ID: 10395644
[TBL] [Abstract][Full Text] [Related]
4. Synergistic interleukin-18 and low-dose interleukin-2 promote regression of established murine neuroblastoma in vivo.
Redlinger RE; Mailliard RB; Lotze MT; Barksdale EM
J Pediatr Surg; 2003 Mar; 38(3):301-7; discussion 301-7. PubMed ID: 12632339
[TBL] [Abstract][Full Text] [Related]
5. CD4 T cells inhibit in vivo the CD8-mediated immune response against murine colon carcinoma cells transduced with interleukin-12 genes.
Martinotti A; Stoppacciaro A; Vagliani M; Melani C; Spreafico F; Wysocka M; Parmiani G; Trinchieri G; Colombo MP
Eur J Immunol; 1995 Jan; 25(1):137-46. PubMed ID: 7843224
[TBL] [Abstract][Full Text] [Related]
6. In vivo effects of recombinant human interleukin 2 on antitumor and antiviral natural immunity in induced or natural murine immunodeficiency states.
Butler LD; Browne CP; Layman NK; Riedl P; Tang J; Marder P; DeLong D; Manetta J; Bobbitt L; Strnad J
Cancer Res; 1988 Nov; 48(21):6081-9. PubMed ID: 3048654
[TBL] [Abstract][Full Text] [Related]
7. Augmentation of natural killer activity, induction of IFN and development tumor immunity during the successful treatment of established murine renal cancer using flavone acetic acid and IL-2.
Hornung RL; Back TC; Zaharko DS; Urba WJ; Longo DL; Wiltrout RH
J Immunol; 1988 Nov; 141(10):3671-9. PubMed ID: 2460546
[TBL] [Abstract][Full Text] [Related]
8. Systemic administration of rIL-12 synergistically enhances the therapeutic effect of a TNF gene-transduced cancer vaccine.
Taniguchi F; Yamagishi H; Fujiwara H; Ueda Y; Fuji N; Yoshimura T; Oka T
Gene Ther; 1998 Dec; 5(12):1677-84. PubMed ID: 10023447
[TBL] [Abstract][Full Text] [Related]
9. IFN-gamma-inducing factor/IL-18 administration mediates IFN-gamma- and IL-12-independent antitumor effects.
Osaki T; Péron JM; Cai Q; Okamura H; Robbins PD; Kurimoto M; Lotze MT; Tahara H
J Immunol; 1998 Feb; 160(4):1742-9. PubMed ID: 9469432
[TBL] [Abstract][Full Text] [Related]
10. Interferon-gamma produced by interleukin-12-activated tumor infiltrating CD8+T cells directly induces apoptosis of mouse hepatocellular carcinoma.
Komita H; Homma S; Saotome H; Zeniya M; Ohno T; Toda G
J Hepatol; 2006 Nov; 45(5):662-72. PubMed ID: 16935390
[TBL] [Abstract][Full Text] [Related]
11. Administration of interleukin-12 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines in mouse hepatocellular carcinoma.
Tatsumi T; Takehara T; Kanto T; Miyagi T; Kuzushita N; Sugimoto Y; Jinushi M; Kasahara A; Sasaki Y; Hori M; Hayashi N
Cancer Res; 2001 Oct; 61(20):7563-7. PubMed ID: 11606395
[TBL] [Abstract][Full Text] [Related]
12. Cellular mechanisms of interleukin-12-mediated neuroblastoma regression.
Redlinger RE; Shimizu T; Remy T; Alber S; Watkins SC; Barksdale EM
J Pediatr Surg; 2003 Feb; 38(2):199-204. PubMed ID: 12596103
[TBL] [Abstract][Full Text] [Related]
13. Rapid generation of potent and tumor-specific cytotoxic T lymphocytes by interleukin 18 using dendritic cells and natural killer cells.
Tanaka F; Hashimoto W; Okamura H; Robbins PD; Lotze MT; Tahara H
Cancer Res; 2000 Sep; 60(17):4838-44. PubMed ID: 10987295
[TBL] [Abstract][Full Text] [Related]
14. Activation of tumor-associated macrophages by the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid induces an effective CD8+ T-cell-mediated antitumor immune response in murine models of lung cancer and mesothelioma.
Jassar AS; Suzuki E; Kapoor V; Sun J; Silverberg MB; Cheung L; Burdick MD; Strieter RM; Ching LM; Kaiser LR; Albelda SM
Cancer Res; 2005 Dec; 65(24):11752-61. PubMed ID: 16357188
[TBL] [Abstract][Full Text] [Related]
15. IL-2/CD40-driven NK cells install and maintain potency in the anti-mesothelioma effector/memory phase.
Jackaman C; Lansley S; Allan JE; Robinson BW; Nelson DJ
Int Immunol; 2012 Jun; 24(6):357-68. PubMed ID: 22354912
[TBL] [Abstract][Full Text] [Related]
16. Combined therapy of mice bearing a lymphokine-activated killer-resistant tumor with recombinant interleukin 2 and an antitumor monoclonal antibody capable of inducing antibody-dependent cellular cytotoxicity.
Kawase I; Komuta K; Hara H; Inoue T; Hosoe S; Ikeda T; Shirasaka T; Yokota S; Tanio Y; Masuno T
Cancer Res; 1988 Mar; 48(5):1173-9. PubMed ID: 3257715
[TBL] [Abstract][Full Text] [Related]
17. Antitumor effects of alpha-interferon and gamma-interferon on a murine renal cancer (Renca) in vitro and in vivo.
Sayers TJ; Wiltrout TA; McCormick K; Husted C; Wiltrout RH
Cancer Res; 1990 Sep; 50(17):5414-20. PubMed ID: 2117482
[TBL] [Abstract][Full Text] [Related]
18. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumors of three district histological types.
Papa MZ; Mulé JJ; Rosenberg SA
Cancer Res; 1986 Oct; 46(10):4973-8. PubMed ID: 3489517
[TBL] [Abstract][Full Text] [Related]
19. Distinct antitumor mechanisms of recombinant interleukin-2 on recombinant interleukin-2-activated killer-sensitive and -resistant murine tumors.
Maekawa R; Kitagawa T; Koizumi K; Sato K; Homma M
J Biol Response Mod; 1989 Dec; 8(6):676-90. PubMed ID: 2600605
[TBL] [Abstract][Full Text] [Related]
20. Eradication of intraperitoneal and distant tumor by adenovirus-mediated interferon-beta gene therapy is attributable to induction of systemic immunity.
Odaka M; Sterman DH; Wiewrodt R; Zhang Y; Kiefer M; Amin KM; Gao GP; Wilson JM; Barsoum J; Kaiser LR; Albelda SM
Cancer Res; 2001 Aug; 61(16):6201-12. PubMed ID: 11507073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]